Veru to Present Three Presentations at the 2022 American Society for Clinical Oncology Annual Meeting on June 3-7
MIAMI, May 31, 2022 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused…
Month: May 2022
Galecto to Participate at Jefferies Healthcare Conference
BOSTON, May 31, 2022 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology…
Agenus Advances Portfolio with 6 Clinical Collaborations
LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company…
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States
Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary…
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons‘ Trap…
Blue Water Vaccines Announces Sponsored Research Agreement Amendment to Continue Funding Universal Influenza Vaccine Development at The University of Oxford
CINCINNATI, May 31, 2022 (GLOBE NEWSWIRE) — Blue Water Vaccines Inc. (“BWV” or “Blue Water…
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD
ISELIN, N.J., May 31, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial…
VBL Therapeutics to Participate in the Jefferies Healthcare Conference
TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:…
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
THE WOODLANDS, Texas, May 31, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today…
Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis
– Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial –…
CRISPR Therapeutics to Host Innovation Day on June 21, 2022
ZUG, Switzerland and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
Gritstone Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of GRANITE and Trial in Progress Poster at ASCO
— Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had…
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications
LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical…
Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying…
PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe
Promising preliminary clinical results validate expansion of study initially into the United Kingdom FLORHAM PARK,…
Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
Updated data from Phase 1/2a study show median duration of response greater than 21 months…
Scientific Leaders Agree on Promise of Enochian BioSciences
LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) — (NASDAQ: ENOB) – Enochian BioSciences is working…
Enlivex Announces New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Meeting
Ovarian Cancer ID8 Study – Survival Probability Source image Stand-alone therapy with PD1 checkpoint inhibitors…
Theratechnologies Announces New Head of Investor Relations
MONTREAL, May 31, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH)…
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical…